Liu Aiping, Philip Jennifer, Vinnakota Kalyan C, Van den Bergh Francoise, Tabima Diana M, Hacker Timothy, Beard Daniel A, Chesler Naomi C
Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin.
Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
Physiol Rep. 2017 Mar;5(6). doi: 10.14814/phy2.13157.
The typical cause of death in pulmonary hypertension (PH) is right ventricular (RV) failure, with females showing better survival rates than males. Recently, metabolic shift and mitochondrial dysfunction have been demonstrated in RV failure secondary to PH In light of evidence showing that estrogen protects mitochondrial function and biogenesis in noncardiovascular systems, we hypothesized that the mechanism by which estrogen preserves RV function is via protection of mitochondrial content and oxidative capacity in PH We used a well-established model of PH (Sugen+Hypoxia) in ovariectomized female rats with/without estrogen treatment. RV functional measures were derived from pressure-volume relationships measured via RV catheterization in live rats. Citrate synthase activity, a marker of mitochondrial density, was measured in both RV and LV tissues. Respiratory capacity of mitochondria isolated from RV was measured using oxygraphy. We found that RV ventricular-vascular coupling efficiency decreased in the placebo-treated SuHx rats (0.78 ± 0.10 vs. 1.50 ± 0.13 in control, < 0.05), whereas estrogen restored it. Mitochondrial density decreased in placebo-treated SuHx rats (0.12 ± 0.01 vs. 0.15 ± 0.01 U citrate synthase/mg in control, < 0.05), and estrogen attenuated the decrease. Mitochondrial quality and oxidative capacity tended to be lower in placebo-treated SuHx rats only. The changes in mitochondrial biogenesis and function paralleled the expression levels of PGC-1 in RV Our results suggest that estrogen protects RV function by preserving mitochondrial content and oxidative capacity. This provides a mechanism by which estrogen provides protection in female PH patients and paves the way to develop estrogen and its targets as a novel RV-specific therapy for PH.
肺动脉高压(PH)的典型死因是右心室(RV)衰竭,女性的生存率高于男性。最近,在继发于PH的RV衰竭中已证实存在代谢转变和线粒体功能障碍。鉴于有证据表明雌激素可保护非心血管系统中的线粒体功能和生物发生,我们推测雌激素维持RV功能的机制是通过保护PH中的线粒体含量和氧化能力。我们在接受/未接受雌激素治疗的去卵巢雌性大鼠中使用了成熟的PH模型(Sugen+低氧)。RV功能指标来自通过对活鼠进行RV导管插入术测量的压力-容积关系。在RV和LV组织中均测量了作为线粒体密度标志物的柠檬酸合酶活性。使用氧电极法测量从RV分离的线粒体的呼吸能力。我们发现,安慰剂治疗的SuHx大鼠的RV心室-血管耦合效率降低(0.78±0.10,而对照组为1.50±0.13,P<0.05),而雌激素可使其恢复。安慰剂治疗的SuHx大鼠的线粒体密度降低(0.12±0.01,而对照组为0.15±0.01 U柠檬酸合酶/毫克,P<0.05),雌激素减弱了这种降低。仅在安慰剂治疗的SuHx大鼠中,线粒体质量和氧化能力往往较低。线粒体生物发生和功能的变化与RV中PGC-1的表达水平平行。我们的结果表明,雌激素通过保留线粒体含量和氧化能力来保护RV功能。这提供了一种机制,通过该机制雌激素可为女性PH患者提供保护,并为开发雌激素及其靶点作为PH的新型RV特异性疗法铺平了道路。